Sat, Nov 23, 2024
[Archive]
Volume 6, Issue 3 (9-2016)
Iran J Ped Hematol Oncol 2016, 6(3): 190-202 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bazi A, Miri-Moghaddam E. Spectrum of β-thalassemia Mutations in Iran, an Update. Iran J Ped Hematol Oncol 2016; 6 (3) :190-202
URL: http://ijpho.ssu.ac.ir/article-1-262-en.html
URL: http://ijpho.ssu.ac.ir/article-1-262-en.html
Dept. of Genetics, Faculty of Medicine, Zahedan University of Medical Sciences, Zahedan-Iran.
Abstract: (5234 Views)
Abstract
β-thalassemia major (β –TM) is the most common thalassemia severe phenotype among Iranians. In recent years, molecular understanding of pathogenesis of β –TM has provided a great opportunity regarding diagnostic issues. Creating comprehensive molecular databases provides highly sensitive diagnostic tools for β –TM and effective prenatal diagnosis (PND) molecular screening tests. Despite a large body of research on molecular basis of β –TM, there are few review papers that consider a general view on the distribution of β –TM mutations in Iran. In the current review, common genetic defects identified in Iranian β –TM patients since 2005 to 2014 have been described. In addition, the prevalences and distributional trends of recognized mutations were discussed. It was found that IVSII-1 (G>A) and IVSI-5 (G>C) were by far the most frequent mutations detected in Iranian patients. Other common reported mutations included FSC 8/9 (+G), IVS I-110 (G>A), FSC 36/37 (–T), IVSI-1 (G>A), IVSI (-25bp), and codon 44 (-C). In conclusion, it was found that molecular profile of β –TM is highly variable among different Iranian populations; in particular, it seems that ethnicity and intra-migration can be most important participating factors in controlling distributional patterns.
Type of Study: Research |
Subject:
Heart
Received: 2015/04/8 | Accepted: 2016/05/18 | Published: 2016/09/3
Received: 2015/04/8 | Accepted: 2016/05/18 | Published: 2016/09/3
References
1. Habibzadeh F, Yadollahie M, Merat A, Haghshenas M. Thalassemia in Iran; an overview. Arch Irn Med. 1998; 1(1): 27-33. [Article]
2. Miri-Moghaddam E, Eshghi P, Moghaddam ES, Hashemi S. Prevalence of hemoglobinopathies in Sistan and Balouchistan province in the southeast of Iran. Sci J Iran Blood Transfus Organ. 2013; 9(4): 406-13. [Article]
3. Samavat A, Modell B. Iranian national thalassaemia screening programme. Bmj. 2004; 329(7475): 1134-7. [Article]
4. Miri-Moghaddam E, Naderi M, Izadi S, Mashhadi M. Causes of new cases of major thalassemia in sistan and balouchistan province in South-East of iran. Iran J Public Health. 2012; 41(11): 67. [Article]
5. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol. 2005; 33(3): 259-71. [Article]
6. Thein SL. The molecular basis of β-thalassemia. Cold Spring Harb Perspect Med. 2013; 3(5): a011700. [Article]
7. Hardison RC, Chui DH, Giardine B, Riemer C, Patrinos GP, Anagnou N, et al. HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server. Hum Mutat. 2002; 19(3): 225-33. [Article]
8. Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, et al. The β-thalassemia mutation spectrum in the Iranian population. Hemoglobin. 2001; 25(3): 285-96. [Article]
9. Rahimi Z, VEYSI RAIGANI A, Merat A, Haghshenas M, Gerard N, Nagel R, et al. Thalassemic mutations in southern Iran. Iran J Med Sci. 2006; 31(2): 70-73. [Article]
10. Rahimi Z, Muniz A, Parsian A. Detection of responsible mutations for beta thalassemia in the Kermanshah Province of Iran using PCR-based techniques. Mol Biol Rep. 2010; 37(1): 149-54. [Article]
11. Rezaee AR, Banoei MM, Khalili E, Houshmand M. Beta-thalassemia in iran: new insight into the role of genetic admixture and migration. ScientificWorldJournal. 2012;2012: 635183. [Article]
12. Akhavan-Niaki H, Derakhshandeh-Peykar P, Banihashemi A, Mostafazadeh A, Asghari B, Ahmadifard MR, et al. A comprehensive molecular characterization of beta thalassemia in a highly heterogeneous population. Blood Cells Mol Dis. 2011; 47(1): 29-32. [Article]
13. Derakhshandeh-Peykar P, Akhavan-Niaki H, Tamaddoni A, Ghawidel-Parsa S, Holakouie Naieni K, Rahmani M, et al. Distribution of β-thalassemia mutations in the northern provinces of Iran. Hemoglobin. 2007; 31(3): 351-6. [Article]
14. Karimi M, Yarmohammadi H, Farjadian S, Zeinali S, Moghaddam Z, Cappellini MD, et al. β-Thalassemia intermedia from southern Iran: IVS-II-1 (G→ A) is the prevalent thalassemia intermedia allele. Hemoglobin. 2002; 26(2): 147-54. [Article]
15. Rajabi A, Karinipoor M, Kaviani S, Arjmandi K, Zeinali S. Paper: Analysis of β-Globin Gene Mutation And G γ XMNI Polymorphism In Thalassemia Intermedia Patiens Referred to ALI-Asghar Hospital, Tehran. [Article]
16. Hosseinpour Feizi MA, Hosseinpour Feizi AA, Pouladi N, Haghi M, Azarfam P. Molecular spectrum of β-thalassemia mutations in Northwestern Iran. Hemoglobin. 2008; 32(3): 255-61. [Article]
17. Miri-Moghaddam E, Zadeh-Vakili A. Profile of β-Thalassemia and its Prenatal Diagnosis in Khorasan-E-Jonobi Province, Iran. Hemoglobin. 2012; 36(5): 456-63. [Article]
18. Galehdari H, Salehi B, Azmoun S, Keikhaei B, Zandian KM, Pedram M. Comprehensive spectrum of the β-thalassemia mutations in Khuzestan, Southwest Iran. Hemoglobin. 2010; 34(5): 461-8. [Article]
19. Dehghanifard A, Shahjahani M, Galehdari H, Rahim F, Hamid F, Jaseb K, et al. Prenatal diagnosis of different polymorphisms of β-globin gene in Ahvaz. Int J Hematol Oncol Stem Cell Res. 2013; 7(2): 17. [Article]
20. Miri-Moghaddam E, Zadeh-Vakili A, Nikravesh A, Sanei Sistani S, Naroie-Nejad M. Sistani Population: a Different Spectrum oF β-Thalassemia Mutations From other Ethnic Groups of Iran. Hemoglobin. 2013; 37(2): 138-47. [Article]
21. Miri‐Moghaddam E, Zadeh‐Vakili A, Rouhani Z, Naderi M, Eshghi P, Khazaei Feizabad A. Molecular basis and prenatal diagnosis of β‐thalassemia among Balouch population in Iran. Prenat Diagn. 2011; 31(8): 788-91. [Article]
22. Saleh-Gohari N, Bazrafshani M. Distribution of β-globin gene mutations in thalassemia minor population of Kerman Province, Iran. Iran J Public Health. 2010; 39(2): 69. [Article]
23. Rahiminejad MS, Zeinali S, Afrasiabi A, Kord Valeshabad A. β-Thalassemia Mutations Found During 1 Year of Prenatal Diagnoses in Fars Province, Iran. Hemoglobin. 2011; 35(4): 331-7. [Article]
24. Mehrabi M, Alibakhshi R, Fathollahi S, Farshchi MR. The Spectrum of β-Thalassemia Mutations in Kermanshah Province in West Iran and its Association with Hematological Parameters. Hemoglobin. 2013; 37(6): 544-52. [Article]
25. Rahimi Z, Muniz A, Akramipour R, Tofieghzadeh F, Mozafari H, Vaisi-Raygani A, et al. Haplotype analysis of beta thalassemia patients in Western Iran. Blood Cells Mol Dis. 2009; 42(2): 140-3. [Article]
26. Haghi M, Khorshidi S, Hosseinpour Feizi MA, Pouladi N, Hosseinpour Feizi AA. β-Thalassemia mutations in the Iranian Kurdish population of Kurdistan and West Azerbaijan provinces. Hemoglobin. 2009; 33(2): 109-14. [Article]
27. Kiani AA, Mortazavi Y, Zeinali S, Shirkhani Y. The molecular analysis of β-thalassemia mutations in Lorestan Province, Iran. Hemoglobin. 2007; 31(3): 343-9. [Article]
28. Yavarian M, Harteveld CL, Batelaan D, Bernini LF, Giordano PC. Molecular spectrum of β-thalassemia in the Iranian province of Hormozgan. Hemoglobin. 2001; 25(1): 35-43. [Article]
29. Ansari SH, Shamsi TS, Ashraf M, Bohray M, Farzana T, Khan MT, et al. Molecular epidemiology of β-thalassemia in Pakistan: far reaching implications. Indian J Hum Genet. 2011; 2(4): 403. [Article]
30. Panja A, Ghosh TK, Basu A. Genetics of Thalassemia in Indian Population. JCNH. 2012; 1(1): 39-46 [Article]
31. Patel AP, Patel RB, Patel SA, Vaniawala SN, Patel DS, Shrivastava NS, et al. β-Thalassemia Mutations in Western India: Outcome of Prenatal Diagnosis in a Hemoglobinopathies Project. Hemoglobin. 2014; 38(5): 329-34. [Article]
32. Abuzenadah AM, Hussein IMR, Damanhouri GA, A-Sayes FM, Gari MA, Chaudhary AG, et al. Molecular basis of β-thalassemia in the western province of Saudi Arabia: identification of rare β-thalassemia mutations. Hemoglobin. 2011; 35(4): 346-57. [Article]
33. Baysal E. Molecular basis of β-thalassemia in the United Arab Emirates. Hemoglobin. 2011; 35(5-6): 581-8. [Article]
34. Hamamy HA, Al-Allawi NA. Epidemiological profile of common haemoglobinopathies in Arab countries. J Community Genet. 2013; 4(2): 147-67. [Article]
35. Al-Azzawie H, AA A-k. Molecular Study on β-Thalassemia Patients in Iraq. Curr Res Microbiol Biotechnol. 2013; 1(4): 160-5. [Article]
36. Najjari A, Asouri M, Gouhari LH, Niaki HA, Nejad ASM, Eslami SM, et al. α: Non-α and Gγ: Aγ globin chain ratios in thalassemia intermedia patients treated with hydroxyurea. Asian Pac J Trop Biomed. 2014; 4(1): S177. [Article]
37. Akbari MT, Izadi P, Izadyar M, Kyriacou K, Kleanthous M. Molecular basis of thalassemia intermedia in Iran. Hemoglobin. 2008; 32(5): 462-70. [Article]
38. Neishabury M, Azarkeivan A, Oberkanins C, Esteghamat F, Amirizadeh N, Najmabadi H. Molecular mechanisms underlying thalassemia intermedia in Iran. Genet Test. 2008; 12(4): 549-56. [Article]
39. Hamid M MF, Akbari MT, Arab A, Zeinali S, Karimipoor M. Molecular analysis of gamma-globin promoters, HS-111 and 3'HS1, in beta-thalassemia intermedia patients associated with high levels of Hb F. Hemoglobin. 2009; 33(6): 428-38. [Article]
40. Nemati H, Rahimi Z, Bahrami G. The Xmn1 polymorphic site 5′ to the Gγ gene and its correlation to the Gγ: Aγ ratio, age at first blood transfusion and clinical features in β-Thalassemia patients from Western Iran. Mol Biol Rep. 2010; 37(1): 159-64. [Article]
41. Arab A, Karimipoor M, Rajabi A, Hamid M, Arjmandi S, Zeinali S. Molecular characterization of β-thalassemia intermedia: a report from Iran. Mol Biol Rep. 2011; 38(7): 4321-6. [Article]
42. Yavarian M, Karimi M, Bakker E, Harteveld CL, Giordano PC. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. haematologica. 2004; 89(10): 1172-8. [Article]
43. Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012; 95(1): 51-6. [Article]
44. Zamani F, Shakeri R, Eslami SM, Razavi SM, Basi A. Hydroxyurea therapy in 49 patients with major beta-thalassemia. Arch Iran Med. 2009; 12(3): 295-7. [Article]
45. Neishabury M, Zamani F, Keyhani E, Azarkeivan A, Abedini SS, Eslami MS, et al. The influence of the BCL11A polymorphism on the phenotype of patients with beta thalassemia could be affected by the beta globin locus control region and/or the Xmn1-HBG2 genotypic background. Blood Cells Mol Dis. 2013; 51(2): 80-4. [Article]
46. Lou Jw, Li Q, Wei Xf, Huang Jw, Xu Xm. Identification of the Linkage of a 1.357 KB β-Globin Gene Deletion and A γ-Globin Gene Triplication in a Chinese Family. Hemoglobin. 2010; 34(4): 343-53. [Article]
47. Nasouhipur H, Banihashemi A, Kamangar RY, Akhavan-Niaki H. Hb Knossos: HBB: c. 82G> T Associated with HBB: c. 315+ 1G> A Beta Zero Mutation Causes Thalassemia Intermedia. Indian J Hematol Blood Transfus. 2014; 30(1): 1-3. [Article]
48. Pepe C, Eberle SE, Chaves A, Milanesio B, Aguirre FM, Gómez VA, et al. A New β0 Frameshift Mutation, HBB: c. 44delT (p. Leu14ArgfsX5), Identified in an Argentinean Family Associated with Secondary Genetic Modifiers of β-Thalassemia. Hemoglobin. 2014; 38(6): 444-6. [Article]
49. Prajantasen T, Teawtrakul N, Fucharoen G, Fucharoen S. Molecular Characterization of a β-Thalassemia Intermedia Patient Presenting Inferior Vena Cava Thrombosis: Interaction of the β-Globin Erythroid Krüppel-Like Factor Binding Site Mutation with Hb E and α+-Thalassemia. Hemoglobin. 2014; 38(6): 451-3. [Article]
50. Liu D, Zhang X, Yu L, Cai R, Ma X, Zheng C, et al. Erythroid Krüppel-like factor mutations are relatively more common in a thalassemia endemic region and ameliorate the clinical and hematological severity of β-thalassemia. Blood. 2014; 124(5): 803-11. [Article]
51. Joly P, Lacan P, Garcia C, Meley R, Pondarré C, Francina A. A novel deletion/insertion caused by a replication error in the β-globin gene locus control region. Hemoglobin. 2011; 35(4): 316-22. [Article]
52. Lee ST, Yoo EH, Kim JY, Kim JW, Ki CS. Multiplex ligation‐dependent probe amplification screening of isolated increased HbF levels revealed three cases of novel rearrangements/deletions in the β‐globin gene cluster. Br J Haematol. 2010; 148(1): 154-60. [Article]
53. Thein SL. Genetic association studies in β-hemoglobinopathies. Hematology Am Soc Hematol Educ Program. 2013; 2013(1): 354-61. [Article]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
